Tag Archives: Rheumatology
Checklists for workflow considerations relating to adalimumab biosimilars
Nonmedical Switching From Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology?
Era of biosimilars in rheumatology: reshaping the healthcare environment
The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases
Rheumatology Biosimilars Landscape
Adalimumab was approved by Food and Drug Administration (FDA) in 2002 for the treatment of rheumatoid arthritis and, in subsequent years, gained approval for the treatment of additional conditions, including plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, hidradenitis suppurativa, inflammatory bowel disease, and uveitis. In 2023, several adalimumab biosimilars from different manufacturers are anticipated to enterContinue reading “Rheumatology Biosimilars Landscape”